期刊文献+

阿奇霉素缓释微丸体外释药影响因素考察

Factors influencing in vitro release of Azithromycin from Sustained-release pellets
下载PDF
导出
摘要 考察影响阿奇霉素缓释微丸体外释药的各种因素,为阿奇霉素缓释制剂的研制提供实验依据。方法选用微晶纤维素为空白丸芯,将阿奇霉素制成缓释微丸,通过测定体外释放度,考察EC粘度及增重、致孔剂用量、释放介质pH值对阿奇霉素缓释微丸体外释药速率的影响。结果 EC粘度、包衣增重、致孔剂用量、释放介质pH值对释药速率有显著影响。结论选用适宜包衣材料及致孔剂,调节包衣增重,可制备具有理想释药行为的阿奇霉素缓释微丸。 OBJECTIVE To investigate the impact of vitro release of Azithromycin sustained-release pellets of various factors,and provide experimental basis for the development of Azithromycin sustained-release formulations.METHODS Selection of microcrystalline cellulose blank pill core made of azithromycin sustained-release pellets,by measuring the in vitro release study EC viscosity,weight gain and pore-forming agents dosage,the release medium pH of in vitro release pill.RESULTS EC viscosity,weight gain,pore-forming agents dosage,the release medium pH had a significant impacts on the release rate.CONCLUSION Selection of suitable coating material and pore-forming agents,adjust coating weight can be used to prepare Azithromycin sustained-release pellets with desired release behavior.
出处 《海峡药学》 2012年第12期9-12,共4页 Strait Pharmaceutical Journal
关键词 阿奇霉素 体外 释药速率 Azithromycin In vitro Release rate
  • 相关文献

参考文献3

二级参考文献21

  • 1FDA批准阿奇霉素缓释型口服混悬剂[J].世界临床药物,2005,26(8):449-449. 被引量:1
  • 2卢美菊.阿奇霉素与红霉素随机对照治疗呼吸道感染的临床疗效[J].安徽医药,2006,10(4):259-260. 被引量:2
  • 3[3]Liu P,Allaudeen H,Chandra R,et al.Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen[J].Antimicrob Agents Chemother,2007,51(1):103-109.
  • 4[4]Chandra R,Liu P,Breen JD,et al.Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin[J].Clin Pharmacokinet,2007,46(3):247-259.
  • 5[5]Blumer JL.Evolution of a new drug formulation:the rationale for high-dose,short-course therapy with azithromycin[J].Int J Antimicrob Agents,2005,26(Suppl 3):S143-147.
  • 6[6]Hadley JA.Value of short-course antimicrobial therapy in acute bacterial rhinosinusitis[J].Int J Antimicrob Agents,2005,26(Suppl 3):S164-169.
  • 7[7]Girard D,Finegan SM,Dunne MW,et al.Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models[J].J Antimicrob Chemother,2005,56(2):365-371.
  • 8[8]Blanco M,Valdes D,Llorente I,et al.Application of NIR Spectroscopy in polymorphic analysis:study of pseudo-polymorphs stability[J].J Pharm Sci,2005,94(6):1336-1342.
  • 9[9]Gandhi R,Pillai O,Thilagavathi R,et al.Characterization of Azithromycin hydrates[J].Eur J Pharm Sci,2002,16(3):175-184.
  • 10[10]Drehobl MA,De Salvo MC,Lewis DE,et al.Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults[J].Chest,2005,128(4):2230-2237.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部